Plain-English translation of NCT06976268 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called BHV-8000 to see if it can help people with early Parkinson's disease. Researchers want to understand whether this treatment is safe, well-tolerated, and actually helps slow or manage Parkinson's symptoms. The study will follow participants for nearly two years to gather this information.
Parkinson's disease affects movement and causes progressive symptoms over time. Currently available treatments have limitations, and researchers are looking for new options that might help people in the early stages of the disease before symptoms become more severe.
You likely qualify if…
You likely don't qualify if…
You would receive either the new medication BHV-8000 (at one of two doses) or a placebo (inactive pill) for the first 48 weeks without knowing which one. After that, everyone moves into the second phase and receives the actual medication for another 48 weeks. Throughout the study, you'll have regular visits with the research team to check how you're doing and monitor for any side effects.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States